Tumescence in HNC Skin Graft Reconstruction

Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Jul 8, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a technique called tumescence to see if it helps improve the success of skin grafts for patients undergoing surgery for head and neck cancer. Tumescence is a method that adds fluid to the area where the skin graft will be placed, which can help reduce blood loss during surgery and may lead to better skin graft uptake. Good skin graft uptake is important because it means less need for extra care afterward and lowers the risk of infection.

To participate in this trial, you need to be at least 18 years old and scheduled for surgery that involves removing cancerous tissue and using a skin graft for reconstruction. You should also be healthy enough to follow the study requirements. If you are pregnant, have had previous radiation treatment, or have certain serious medical conditions, you may not be eligible. If you join the study, you will be randomly assigned to receive either the tumescence technique or the standard care and will be closely monitored during your recovery. This research could help improve outcomes for future patients needing similar surgeries.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria Patients must meet all of the following criteria to be eligible for study entry.
• • 1. Ability to adhere to the study visit schedule and other protocol requirements.
• • 2. Men and women ≥18 years of age.
• • 3. Life expectancy ≥ 3 months.
• • 4. Planned surgery for head and neck cancer ablation requiring split-thickness skin grafting for reconstruction of free flap donor sites from the forearm and fibula.
• • Exclusion Criteria Patients who meet any of the following criteria will be excluded from study entry.
• • 1. Pregnant or lactating women.
• • 2. History of prior radiation.
• • 3. Any significant medical condition which, in the opinion of the investigator, will not be appropriate for the study.
• • 4. Severe infection that in the opinion of the investigator would interfere with patient safety or compliance on trial within 4 weeks prior to enrollment.